



FY23 Financial Results and Business Highlights

22 February 2024



Your speakers today



Kevin Helash
Chief Executive Officer



Douglas Minder
Chief Finance Officer



Carlo Boutton
Chief Scientific Officer

Agenda

- FY 23 operational highlights
- AGROBODY Foundry™ 2.0
- FY 23 financial results
- Outlook 2024
- Q&A



Disclaimer



This presentation, including the oral presentation (together, the “Materials”) has been prepared by the management of Biotallys NV (the “Company”). The Materials must be treated confidentially and may not be distributed, passed on or otherwise disclosed. The Materials serve information purposes only and do not constitute a prospectus or any offer for sale or subscription of, or solicitation or invitation to buy or subscribe for, any securities of the Company. The Company’s business, operations, financial situation and prospects are subject to risks and uncertainties. A description of the most important risks and uncertainties can be found in the Company’s annual report available on its website (www.Biotallys.com)

This presentation includes market share and industry data, which were obtained by the Company from industry publications, press releases, data published by government agencies, industry reports prepared by consultants and other market data providers and internal surveys. The third party sources the Company has used generally state that the information they contain has been obtained from sources believed to be reliable. Some of these third party sources also state, however, that the accuracy and completeness of such information is not guaranteed and that the projections they contain are based on significant assumptions. As the Company does not have access to the facts and assumptions underlying such market data, or statistical information and economic indicators contained in these third party sources, the Company is unable to verify such information and, while the Company believes it to be reliable, it cannot guarantee its accuracy or completeness.

In addition, certain information in this document is not based on published data obtained from independent third parties or extrapolations therefrom, but rather is based upon the Company’s best estimates, which are in turn based upon information obtained from trade and business organizations and associations, consultants and other contacts within the industries in which the Company operates, information published by its competitors and its own experience and knowledge of conditions and trends in the markets in which it operates. The Company cannot provide any assurance that any of the assumptions that it has made while compiling this data from third party sources are accurate or correctly reflect its position in the industry and none of its internal estimates have been verified by any independent sources. The Company makes no representation or warranty as to the accuracy or completeness of this information. The Company has not independently verified this information and, while the Company believes it to be reliable, it cannot guarantee its accuracy.

You are responsible for protecting yourself against viruses and other destructive items. You are accessing the Materials is at your own risk and it is your responsibility to take precautions to ensure that they are free from viruses or other items of a destructive nature.

The Materials are provided in conjunction with the oral presentation held by the Company and should not be taken out of context.

The information contained in the Materials is subject to change without prior notice. The presentation of the Materials (or any part hereof) shall not create any implication that there has been no change in the information contained in the Materials since the date hereof or that there has been no change in the business or financial position of the Company or its subsidiary since the date hereof. The Company does not undertake to provide any additional information, update or keep current information contained in the Materials, or to remedy any omissions in or from the Materials and any opinions expressed in the Materials are subject to change without prior notice. The foregoing is in any event without prejudice to the Company’s obligations under applicable law in relation to disclosure.

The Materials contain certain forward-looking statements, sometimes identified by the words “believes,” “expects,” “predicts,” “intends,” “projects,” “plans,” “estimates,” “aims,” “foresees,” “anticipates,” “targets,” and similar expressions, which speak only as at the date of the Materials. Such statements reflect current views with respect to future events and are subject to risks and uncertainties. Forward-looking statements are based on current plans, estimates, projections and expectations. These statements are based on certain assumptions that may prove to be erroneous. No representations or warranties, express or implied, are given as to the achievement or reasonableness of, and no reliance should be placed on, such forward-looking statements, including any projections, estimates forecasts or targets contained herein.

Nothing in this presentation constitutes an offer of securities for sale in the EEA, the United Kingdom, Switzerland, Japan, the United States or elsewhere. The securities of the Company are not registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered, sold or otherwise transferred within the United States (as such term is defined in Regulation S under the Securities Act) unless registered under the Securities Act or pursuant to an exemption from such registration. There is no intention to register securities of the Company under the Securities Act.

You acknowledge that all industrial and intellectual property rights to this presentation are and shall remain vested in the Company. By attending this presentation or accessing the Materials you shall not acquire any right, title, license to use, or interest in the presentation or the Materials.

All of the trademarks, service marks and logos displayed in the Materials, including but not limited to Biotallys, AGROBODY, EVOCA are registered and unregistered trademarks of the Company or one of its affiliates. Except as expressly provided in the Materials, you may not reproduce, display or otherwise use trademarks without first obtaining the Company’s written permission.

Biotallys and each of their logos are commercial names, trademarks or registered trademarks owned by Biotallys NV.

Focus on core capabilities

Focus on

1. Ongoing regulatory review in the U.S. and Europe, while exploring options to submit in other regions
2. AGROBODY 2.0 technology platform
3. Partnerships – manufacturing and commercial
4. Funding for growth





EVOCA™: a novel tool for biocontrol







EVOCA confirms in independent field trials US

Percent control of harvest bunch severity,
relative to untreated controls




In a rotation program with different sprays, an application with Evoca at the flowering window provides significantly better results than a chemical pesticide

Innovative pipeline focusing on biofungicides and bioinsecticides


 Program	 Target	 Market	Discovery	Early Development	Late Development	Registration
EVOCA 1 st generation	Botrytis, powdery mildew	High-value fruits & vegetables				
EVOCA Next Generation	Botrytis, powdery mildew	High-value fruits & vegetables				
BioFun-6	Botrytis, powdery mildew	High-value fruits & vegetables				
BioFun-7 <small>BILL & MELINDA GATES foundation</small>	Cercospora spp. (leafspot disease)	Cowpeas and other legumes				
BioFun-4	Oomycetes (water mold)	High-value fruits & vegetables				
BioIns-2 <small>syngenta</small>	Key insect pests	Non-disclosed				

AGROBODY Foundry™ 2.0: from platform validation to a next generation of the technology platform




A more targeted discovery approach

Separate the wheat from the chaff early in the AGROBODY™ discovery process



The 3 P's of an ideal AGROBODY™ biocontrol



Pipeline programs - approach



Other ongoing programs next to EVOCA and EVOCA NG

- **BioFun-4**, aimed at targeting Oomycetes in fruits and vegetables
 - Targeted and shotgun approach
- **BioFun-6**, aimed at targeting botrytis, powdery mildew and anthracnose in fruits and vegetables
 - Shotgun approach
- **BioFun-7**, aimed at targeting leafspot disease in cowpeas and other legumes, in collaboration with the Bill & Melinda Gates Foundation
 - Targeted and shotgun approach
- **BioIns-2**, aimed at targeting key pests, in collaboration with Syngenta Crop Protection
 - Targeted approach

New programs

- Expectation to initiate **at least 1 new program per year** on the AGROBODY Platform 2.0.
 - Targeted approach

De-risk, accelerate and grow through strategic partnerships

Science and Technology



Pipeline Product



Product Development



Distribution



Manufacturing



Regulatory



Key Milestones for Biotallys



EVOCA™ Registration

- Obtain product approval for EVOCA in the U.S. & Europe, while exploring options to submit in other regions such as Latin America



AGROBODY Foundry™ 2.0

- Leverage platform to secure further strategic crop protection R&D collaborations
- Upgrade platform capabilities towards exponential potency and costs targets
- Expand platform potential in adjacent food protection markets



Commercial Agreements

- Finalize partnership agreement(s) for commercial production and distribution of EVOCA NG & BioFun-6



Funding

- Secure additional funding to extend the company's runway

Key financials – FY 2023

In € thousand	December 31, 2023	December 31, 2022
Other operating income	2,611	2,949
Research and development expenses	(16,608)	(18,813)
General and administration expenses	(5,708)	(5,081)
Marketing expenses	(1,186)	(1,586)
Operating loss	(20,891)	(22,531)
Loss for the period	(20,510)	(22,731)
Basic and diluted loss per share (in EUR)	(0.65)	(0.74)
Net cash inflow (outflow) for the period	(12,521)	(22,017)
Cash and cash equivalents	21,570	34,096

Q&A



Kevin Helash
Chief Executive Officer



Douglas Minder
Chief Finance Officer



Carlo Boutton
Chief Scientific Officer

